The Gut Microbiome in HIV Pathogenesis: Interconnections Between Dysbiosis, Immune Dysfunction, and Viral Persistence
Open Access
- 27 May 2026
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (11) , 4830
Abstract
The human gut microbiome is essential for immune regulation and mucosal homeostasis, functions that are profoundly disrupted during HIV infection. Early viral replication in the gut-associated lymphoid tissue (GALT) triggers a self-reinforcing cycle of CD4+ T-cell depletion, epithelial barrier breakdown, and increased microbial translocation. This persistent immune activation continues even under effective antiretroviral therapy (ART). A growing body of evidence indicates that HIV infection is consistently associated with alterations in gut microbial communities. This dysbiosis is typically characterized by fewer beneficial butyrate-producing commensal bacteria and an enrichment of pro-inflammatory microbial taxa. It also involves disturbances in key microbial metabolites, including short-chain fatty acids (SCFAs) and tryptophan catabolites. Such changes not only exacerbate systemic inflammation but may also contribute to incomplete immune reconstitution and the persistence of latent viral reservoirs despite long-term ART. In this review, we summarize current knowledge of microbiome–HIV interactions, with particular emphasis on the mechanisms through which gut dysbiosis contributes to immune dysfunction and viral persistence. We discuss recent advances in multi-omics technologies, as well as experimental systems such as gnotobiotic and humanized mouse models and intestinal organoid platforms that are helping to elucidate these complex interactions. Furthermore, we evaluate emerging microbiome-targeted interventions—including probiotics, prebiotics, fecal microbiota transplantation, and engineered bacterial therapeutics—and consider their potential role as adjunctive strategies in HIV treatment and cure research. By integrating microbiological, immunological, and clinical perspectives, this review highlights key knowledge gaps and outlines future research directions aimed at harnessing the gut microbiome as a novel therapeutic avenue in HIV management and eradication.Keywords
This publication has 79 references indexed in Scilit:
- Chromatin Potential Identified by Shared Single-Cell Profiling of RNA and ChromatinCell, 2020
- Curing HIV: Seeking to Target and Clear Persistent InfectionCell, 2020
- Establishing or Exaggerating Causality for the Gut Microbiome: Lessons from Human Microbiota-Associated RodentsCell, 2020
- HIV and the Gut Microbiota: Composition, Consequences, and Avenues for AmeliorationCurrent HIV/AIDS Reports, 2019
- Microbiome therapeutics — Advances and challengesAdvanced Drug Delivery Reviews, 2016
- Role of the Microbiota in Immunity and InflammationCell, 2014
- Cardiovascular Disease and HIV InfectionCurrent HIV/AIDS Reports, 2013
- Residual Immune Dysregulation Syndrome in Treated HIV infection2013
- Reactivation of latent HIV-1 by a wide variety of butyric acid-producing bacteriaCellular and Molecular Life Sciences, 2012
- Microbial Colonization Drives Expansion of IL-1 Receptor 1-Expressing and IL-17-Producing γ/δ T CellsCell Host & Microbe, 2010